change was seen in eosinophil count or in inflammatory markers post treatment. In the sero-positive group 23% had past and current eosinophilia, but this was not statistically different from sero-negative patients. 9/13 reportable charcoal stool cultures were negative. No patients with Strongyloides were taking steroids, compared to 25% of sero-negative patients. In both groups, >40% were on two or more immunosuppressants.

**Conclusion** There is a high sero-prevalence of Strongyloides in migrant IBD patients. Patients from Asia demonstrated the highest prevalence. Eosinophilia and raised inflammatory markers were not predictive of positive serology, most likely due to the high rate of immunosuppression. We cannot confirm all sero-positive patients were infected; published data supports the specificity of Strongyloides serology for current infection. We recommend ECCO guidelines and current British Society of Gastroenterology guidelines are adapted to include targeting IBD patients who originate from endemic areas and serological testing be first line. Follow-up of patients is required to assess the impact of treatment on IBD activity.

**Competing interests** None declared.

**REFERENCES**


---

**PWE-236 WHITE CELL APHAERESIS (WCA) WITH ADACOLUMN IS EFFECTIVE IN SELECTED CASES OF CHRONIC REFRACTORY COLITIS WITH HIGH HISTOLOGICAL ACTIVITY**

doi:10.1136/gutjnl-2012-302514d.236

P Premchand,*, L Ford, D Venkama. Department of Gastroenterology, Queens Hospital Romford, Romford, UK

**Introduction** Treatment options for patients with chronic refractory colitis are limited. White cell apheresis (WCA) is effective in inducing clinical remission in chronic refractory colitis in patients with a strong inflammatory burden at baseline and histologically active disease. Previous multinational sham controlled trials have demonstrated significant improvement when patients with high histological activity (modified Rileys score) are selected for treatment.

**Methods** A prospective study was conducted in 30 patients with severe steroid-dependent or steroid-refractory ulcerative colitis referred for WCA. Inclusion criteria were (i) high disease activity score (partial Mayo score ≥6) (ii) Intractable symptoms despite treatment with steroids and/or immunosuppressants (iii) Severe disease at endoscopy and histologically. The aim was to induce clinical and IBD-Q remission at 12 weeks. A Mayo score ≤3 defined clinical remission. The 32 item Inflammatory Bowel Disease questionnaire (IBD-Q) was used to assess quality of life prior to treatment and at 12 weeks.

**Results** Patient Characteristics: Prior to treatment 28 patients (93.3%) were prescribed 5-ASA compounds. 12 patients (40%) were prescribed topical therapies (5-ASA enemas or suppositories/steroids enemas). 27 patients (90%) were steroid dependent (Prednisolone mean dose 21.1 mg, median 20 mg). Three patients (10%) were steroid refractory (no response to high dose oral steroids). 15 patients (45.3%) were prescribed Azathioprine of the remainder all had documented intolerance or a contraindication. One patient (3.3%) was prescribed six Mercaptopurine. Five patients had failed Infliximabs (16.6%) and in one patient (3.3%) it was contraindicated. 1 patient (3.3%) had failed intramuscular Methotrexate.

**Outcomes:** At week 12 clinical remission (Mayo score ≤3) was achieved in 22 patients (73.3%), 12 patients (60%) were no longer prescribed oral steroids. IBD-Q remission at week 12 was achieved in 19 patients (63.3%). Of the remainder, five patients (16.6%) achieved an IBD-Q response. Of eight patients (26.6%) who failed to achieve clinical remission at 12 weeks, one achieved delayed remission at 20 weeks. Of the remaining seven treatment failures, five underwent colectomy (66.6%).

**Conclusion** WCA can be effective in inducing clinical remission and improving quality of life (IBD-Q) indices in chronic severe steroid refractory ulcerative colitis with highly active disease histologically. This data series suggests WCA should be considered before colectomy in this challenging patient group.

**Competing interests** None declared.

**REFERENCES**